Indian pharmaceutical companies, which are increasingly choosing to settle patent litigation with global drug majors in the US, would have to be more cautious now.
Anil Dhirubhai Ambani Group company Reliance Infrastructure (R-Infra) will soon be the official owner of the second phase of the Mumbai Metro project. The state government and the company will sign a concession agreement for the Rs 11,000-crore (Rs 110 billion) project on Thursday, according to sources.
Indian engineering and management institutes, which have set up bases in Dubai, are facing a 13-60 per cent dip in admissions due to the economic crisis in the city, which is one of the seven emirates of the United Arab Emirates (UAE).
Hyderabad-based Indian School of Business (ISB) is off to a flying start this season. Citi Group has offered an analyst investment banker's position with so far the highest offer of Rs 40 lakh per annum, followed by a Rs 33-lakh offer by Parthenon Group, a consulting firm.
The court's stand is expected to help Wockhardt conclude the deal within a month's time.
The IIMs will begin final placements in March 2010.
The 'First Status Report on Technology Business Incubation' in India also stated that 20 to 30 per cent of incubated companies make it big.
The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world's largest generics maker. Teva is next on the list. Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.
Orders are flowing for the water and wastewater treatment industry, as leading players in the domestic market such as VA Tech Wabag, Larsen and Toubro, Thermax and IVRCL Infra have bagged over Rs 2,500 crore (Rs 25 billion) worth of orders in the past two-to-three months.
Novartis markets Nilotinib globally as Tasigna, which is used as the second-line therapy for Gleevec-resistant patients in the case of chronic myelogenous leukemia.
However, analysts say it is not immediately clear if the merger would have any impact on Novartis India, the listed Indian subsidiary of the company.
This increase is despite the decreased growth of drug sales in the US - the world's largest market - which has seen a tightening of regulations and aggressive competition.
These universities are a part of the ministry's 'brain gain' policy to attract talent from all over the world. Human Resources Development Minister Kapil Sibal had last August announced that 14 Innovation Universities will be set up in the country under the 11th Five-year Plan (2007-12).
People will have to pay 50p-Re 1 more per litre of petrol and diesel when 11 cities in India move to the Euro IV emission norm, and the rest of the country to Euro III, in April 2010.
Last year, over 200 companies adopted 300 ITIs in the country and the involvement is gaining pace.
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy's Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales.
Day Zero was created when demand for IIM graduates had peaked and the institutes had to resort to creative mathematics to accommodate big recruiters without offending the existing ones. Falling job market has forced the B-schools to review the strategy, including placement fee revision.
Results of the Common Admission Test could get delayed with Indian Institutes of Management and Prometric, which conducted the online test, still to decide a new date for conducting the exam for students who could not give their exam due to technical glitches.
R-Infra quoted Rs 42-crore (Rs 420-million) premium over the bids of rival companies such as GVK Power and Infrastructure Limited, GMR Infrastructure, B Sennaih and C&C, JMC Srei and Sadhbhav, sources told Business Standard.
Pankaj Sarma (name changed), associate professor with an Indian business school, earns Rs 1 lakh every month for evaluating papers written by students in the US. This is apart from his salary of Rs 60,000 as per University Grants Commission scale.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances